Lupin
- Market Cap
- ₹92,098 Cr
- P/E
- 17.69
Key Fundamentals
MidcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 29.90%
- Debt to Equity
- 0.26
- EPS (TTM)
- ₹113.88
- Book Value
- ₹525.92
- Market Cap
- ₹92,098 Cr
- P/E (TTM)
- 17.69
- P/B
- 3.83
- ROE
- 28.70%
- Dividend Yield
- 0.90%
- EBITDA
- ₹9,240 Cr
- 52W High
- ₹2,529.50
- 52W Low
- ₹1,892.90
- Day Range
- ₹1,985.10 – ₹2,014.00
- Volume
- 6,30,830
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 2,014.00 | 17.69 | 92,098 | 3.83 | 0.91% | 28.70% | 29.90% | 30,746 | 5,222 | |
| Median 8 companies | 1,949.45 | 41.35 | 1,21,840 | 4.69 | 0.70% | 17.40% | 19.15% | 29,259 | 3,109 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 57
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 89
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 73
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 48
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 11
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has delivered good profit growth of 37.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 17.1%
- Company's working capital requirements have reduced from 46.4 days to 28.0 days
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 6 | 7 |
| Oscillators | Bullish | 1 | 6 | 2 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Neutral
Key readings
- RSI (14)
- 53.46
- Neutral
- MACD (12,26,9)
- −5.08
- Bullish
- SMA (50)
- 2,012.25
- Bullish
- SMA (200)
- 2,230.63
- Bearish
As of
Analyst Rating
15 of 35 analysts rate Buy, 12 Hold, 8 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +6.97% |
|---|---|
| 5Y | +13.02% |
| 3Y | +18.88% |
| 1Y | +23.12% |
| TTM | +24.23% |
Net profit
| 10Y | +8.96% |
|---|---|
| 5Y | +34.25% |
| 3Y | +128.64% |
| 1Y | +61.98% |
| TTM | +20.13% |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | +32.12% |
| 3Y | +56.95% |
| 1Y | +144.47% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +3.30 pp |
|---|---|
| 5Y | +12.26 pp |
| 3Y | +18.85 pp |
| 1Y | +5.95 pp |
| TTM | +2.81 pp |
Revenue by year
| Mar 2017 | ₹17,367 Cr |
|---|---|
| Mar 2018 | ₹15,797 Cr |
| Mar 2019 | ₹14,665 Cr |
| Mar 2020 | ₹15,375 Cr |
| Mar 2021 | ₹15,163 Cr |
| Mar 2022 | ₹16,405 Cr |
| Mar 2023 | ₹16,642 Cr |
| Mar 2024 | ₹20,011 Cr |
| Mar 2025 | ₹22,708 Cr |
| Mar 2026 | ₹27,958 Cr |
Net profit by year
| Mar 2017 | ₹2,565 Cr |
|---|---|
| Mar 2018 | ₹258 Cr |
| Mar 2019 | ₹615 Cr |
| Mar 2020 | −₹270 Cr |
| Mar 2021 | ₹1,228 Cr |
| Mar 2022 | −₹1,528 Cr |
| Mar 2023 | ₹448 Cr |
| Mar 2024 | ₹1,936 Cr |
| Mar 2025 | ₹3,306 Cr |
| Mar 2026 | ₹5,355 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Lupin Ltd trades at ₹1,998.8 with a market cap of ₹91,403 crore as of 2026-11-19. The company has delivered strong profit growth of 37% CAGR over five years with an ROE of 23.79% and conservative leverage at a debt-to-equity ratio of 0.29, though the stock is down 2% over the past year and sits roughly 21% below its 52-week high of ₹2,529.5.
- Compounded profit growth of 37% CAGR over the last 5 years and 140% over the last 3 years indicates a sharp earnings recovery and expansion cycle
- ROE of 23.79% and ROCE of 28.42% as of 2026-11-19 reflect efficient capital allocation relative to many Indian pharma peers
- TTM revenue growth of 24% shows continued top-line momentum, well above the 10-year compounded sales growth rate of 7%
- Low debt-to-equity ratio of 0.29 provides balance sheet flexibility for R&D investment, acquisitions, or capacity expansion without undue financial risk
- Working capital days have compressed from 46.4 to 28.0, improving cash conversion and freeing up capital for reinvestment
- TTM profit growth of 30% on top of already elevated 3-year and 5-year profit CAGRs suggests earnings momentum is still intact
- Consistent dividend payout of 17.1% with a current dividend yield of 0.91% provides a modest income stream while retaining earnings for growth
- PE of 17.55x as of 2026-11-19, combined with 30% TTM earnings growth, implies a PEG ratio below 1x on trailing numbers, which some investors view favourably
- The stock has delivered a negative 1-year return of -2%, underperforming broader Indian equity indices and signalling potential near-term sentiment headwinds
- Current price of ₹1,998.8 is approximately 21% below the 52-week high of ₹2,529.5, indicating a meaningful correction that may reflect changing growth expectations
- 10-year compounded sales growth of only 7% suggests the recent 24% TTM revenue growth may represent a cyclical peak rather than a sustainable trajectory
- 10-year compounded profit growth of 10% contrasts sharply with the 3-year figure of 140%, highlighting that much of the recent profit surge may be a recovery from a low base rather than structural improvement
- 10-year ROE averages only 10% compared to the last year's 29%, raising questions about whether current high-return levels can persist through industry cycles
- 10-year stock CAGR of just 4% shows that long-term shareholders have seen limited compounding despite recent operational improvement
- Price-to-book of 3.8x means the market is pricing significant goodwill and intangible value; any earnings miss could trigger a de-rating
- As a global generics-focused pharma company, Lupin faces regulatory risk from agencies such as the US FDA, where adverse inspection outcomes or pricing pressure could materially impact revenue and margins
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Lupin is executing well on its US generics pipeline, landing two first-to-file exclusivity launches (Raltegravir, Amifampridine) and expanding its biosimilar footprint in Europe. However, a 22% YoY drop in Q2FY27 net profit despite revenue growth signals margin pressure that bears watching. The trend on product launches and approvals is clearly positive, but profitability improvement will be key to sustaining momentum in the near term.
- Q2FY27 net profit drops 22% Nov 3
Consolidated PAT declined 22% YoY to ₹11,553 mn in Q2FY27, despite 11% YoY revenue growth driven by pharmaceutical sales.
- Raltegravir US launch with exclusivity Nov 3
Lupin launched Raltegravir 600 mg tablets in the US as the first-to-file generic, securing 180-day exclusivity for this HIV treatment.
- US FDA nod for Amifampridine Nov 2
Received US FDA approval for Amifampridine 10 mg tablets with first-to-file status, eligible for 180 days of shared generic exclusivity.
- Ranibizumab biosimilar launched in Europe Nov 12
Partner Sandoz launched Ranluspec, a Ranibizumab biosimilar, across Europe excluding Germany on November 12, 2026.
- Akhil Gupta appointed independent director Nov 3
Akhil Gupta was appointed as Additional Director (Non-Executive, Independent) effective November 3, 2026, with a postal ballot for shareholder approval opening November 17.
- Brian Savage named Chief Legal Officer Oct 22
Brian Savage was appointed President and Chief Legal Officer effective October 22, 2026, bringing extensive global pharma legal experience.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 | 7,827 |
| Expenses | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 | 5,783 |
| Operating Profit | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 | 2,044 |
| OPM % | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% | 26% |
| Other Income | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | −312 | 141 | 130 | 127 |
| Interest | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 | 106 |
| Depreciation | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 | 486 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | −131 | — | — |
| PBT | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 | 1,580 |
| Tax % | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% | 27% |
| Net Profit | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 | 1,155 |
| EPS (₹) | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 | 25.26 |
| YoY Sales growth | 22 | 20 | 12 | 16 | 13 | 11 | 14 | 12 | 24 | 24 | 32 | 32 | 11 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 | 30,746 |
| Expenses | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 19,798 | 21,505 |
| Operating Profit | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 8,160 | 9,241 |
| OPM % | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1.3% | 10% | 19% | 23% | 29% | 30% |
| Other Income | 235 | 184 | 106 | −1,310 | 91 | −134 | 138 | 210 | 151 | 131 | 202 | 523 | −45 |
| Interest | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 434 | 450 |
| Depreciation | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,376 | 1,698 |
| PBT | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | −1,372 | 716 | 2,422 | 4,015 | 6,873 | 7,047 |
| Tax % | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | 22% | — |
| Net Profit | 2,444 | 2,270 | 2,565 | 258 | 615 | −270 | 1,228 | −1,528 | 448 | 1,936 | 3,306 | 5,355 | 5,221 |
| EPS (₹) | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | −5.95 | 26.81 | −33.62 | 9.45 | 42.01 | 71.88 | 116.65 | 113.88 |
| Div. Payout % | 14% | 15% | 13% | 90% | 37% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 24% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 42% | 19% | 17% | 15% | — |
| Sales growth | 13 | 12 | 22 | −9 | −7 | 5 | −1 | 8 | 1 | 20 | 13 | 23 | 24 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 22,357 | 23,959 |
| Borrowings | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 4,783 | 4,158 | 4,542 | 2,922 | 5,448 | 6,616 | 6,180 |
| Other Liabilities | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,844 | 5,340 | 5,794 | 6,539 | 6,327 | 9,082 | 9,680 |
| Total Liabilities | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 | 39,911 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,994 | 13,332 |
| CWIP | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 1,016 | 931 |
| Investments | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,670 | 4,456 |
| Other Assets | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 22,466 | 21,191 |
| Total Assets | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 | 39,911 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 2,733 | −382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 | 7,334 |
| Investing | −1,034 | −6,769 | −2,527 | 470 | −3,282 | 1,107 | −1,240 | 1,292 | −1,287 | −1,712 | −4,172 | −3,865 |
| Financing | −197 | 5,836 | 433 | −1,492 | 744 | −891 | −1,885 | −1,572 | −337 | −2,184 | 1,732 | −846 |
| Net Cash Flow | 1,502 | −1,315 | 2,019 | 729 | −872 | 1,685 | −1,303 | 87 | 273 | −248 | 560 | 2,624 |
| Free Cash Flow | 1,865 | −6,164 | 1,513 | 261 | 706 | 798 | 1,150 | −531 | 436 | 2,732 | 1,347 | 5,527 |
| CFO/EBITDA | 101 | 21 | 117 | 73 | 102 | 84 | 99 | 146 | 124 | 105 | 74 | 105 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 | 86 |
| Inventory Days | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 | 303 |
| Days Payable | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 | 208 |
| Cash Conversion Cycle | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 | 181 |
| Working Capital Days | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 | 28 |
| ROCE % | 40% | 24% | 19% | 10% | 10% | 9% | 9% | −7% | 6% | 16% | 21% | 30% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lupin insights
72 extracted metrics across FY00–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026PPT
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 8 Jul 2026
- 9 Oct 2025
- 30 Jun 2025
- 25 Apr 2024
- 23 Feb 2023
- General announcements 12 Nov 2026
Frequently Asked Questions about Lupin
What does Lupin Ltd do?
Where is Lupin Ltd (LUPIN) listed?
Which sector does Lupin Ltd belong to?
What is the market capitalisation of Lupin Ltd?
What is the PE ratio of Lupin Ltd?
What is the 52-week high and low of Lupin Ltd?
Does Lupin Ltd pay dividends?
What is the Return on Equity (ROE) of Lupin Ltd?
Company Information
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LUPIN.md for Lupin Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.